Citations

Institution: Mayo Clinic Clear

Showing 10 of 108081 citations.

Thrombosis in multiple myeloma (MM)
Cesarman‐Maus, Gabriela , Braggio, Esteban , Fonseca, Rafaël , Braggio, Esteban , Cesarman-Maus, Gabriela , Fonseca, Rafael

Hematology | June 21, 2012 | Volume: 17 | Issue: sup1 | Pages: s177-s180

10.1179/102453312x13336169156933 | PMID 22507814 Get It

A comprehensive analysis of hemoglobin variants by high‐performance liquid chromatography (HPLC)
Szuberski, Jessica, Oliveira, Jennifer L. , Hoyer, J. D., Herrick, Jennifer L.

International Journal of Laboratory Hematology | June 20, 2012 | Volume: 34 | Issue: 6 | Pages: 594-604

10.1111/j.1751-553x.2012.01440.x | PMID 22713122 Get It

SummaryIntroductionHigh‐performance liquid chromatography (HPLC) is a method commonly used for the detection of hemoglobin (Hb) variants. In addition to providing precise quantitation of Hb A2 and Hb F, the reported retention time and peak shape of a high number of hemoglobin (Hb) variants are very helpful for presumptive identification. However, there is a scarcity of summarized data in the literature of the mobility of Hb variants on this method.MethodsA total of 383 Hb variants were studied on the Bio‐Rad Variant ™ Classic HPLC instrument. Hb variant identification used a number of methods, including confirmation by DNA sequencing in at least one case for all alpha and beta chain Hb variants.ResultsRetention time data and the number of occurrences of each Hb variant were obtained. This showed that rare Hb variants can have similar retention times to the five most common alpha or beta chain Hb variants.ConclusionHPLC is a very powerful tool in the evaluation of Hb variants, particularly when combined with other methods. However, it should not be used as a stand‐alone method for definitive identification of Hb variants.
Acellular Fetal Bovine Dermal Matrix for Treatment of Chronic Ulcerations of the Midfoot Associated With Charcot Neuroarthropathy
Kavros, Steven J.

Foot & Ankle Specialist | June 20, 2012 | Volume: 5 | Issue: 4 | Pages: 230-234

10.1177/1938640012449037 | PMID 22715495 Get It

Background. Gross deformity of the foot in Charcot neuroarthropathy can lead to collapse and subsequent ulceration, infection, amputation, or premature death. This study evaluated healing of midfoot ulcerations of Charcot neuroarthropathy using PriMatrix, a novel acellular fetal bovine dermal matrix. Methods. In this retrospective analysis, 20 patients with ulcerations of the midfoot associated with Charcot neuroarthropathy were treated with either PriMatrix in addition to standard wound care (PriMatrix group,n = 12) or standard wound care alone (control group, n = 8). All patients had chronic, nonhealing foot ulcerations of at least 2250 mm 3 for a minimum of 30 days duration. All foot ulcerations were full thickness with subcutaneous involvement. Ankle brachial index ≥0.90 and/or transcutaneous oximetry (TcPo 2 ) ≥40 mm Hg at the periulcer site was necessary for inclusion. Patients were excluded if they had acute or chronic osteomyelitis of the foot. Results. Demography, risk factors, baseline severity of Charcot neuroarthropathy, and wound volume (control 4078 mm 3 , PriMatrix 3737.5 mm 3 , P = nonsignificant) were similar between treatment groups. Mean time to healing in the PriMatrix group (116 days, 95% CI = 109-123) was significantly shorter than in the control group (180 days, 95% confidence interval [CI] = 171-188); P < .0001. A significantly faster rate of healing was observed with PriMatrix (87.9 mm 3 /wk, 95% CI = 115.2% to 60.6%) compared with control (59.0 mm 3 /wk, 95% CI = 72.8% to 45.3%); P < .0001). Conclusions. The significantly faster rate of healing and steeper slope of volume reduction in the PriMatrix group warrants further investigation into its effects on healing of neuropathic ulcerations and potential limb salvage. Levels of Evidence: Therapeutic, Level IV
Endoscopic-Ultrasound-Guided Tissue Sampling Facilitates the Detection of Local Recurrence and Extra Pelvic Metastasis in Pelvic Urologic Malignancy
Gleeson, Ferga C. , Clain, Jonathan E., Karnes, R. Jeffrey , Rajan, Elizabeth , Topazian, Mark , Wang, Kenneth K. , Levy, Michael J.

Diagnostic and Therapeutic Endoscopy | June 19, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-6

10.1155/2012/219521 | PMID 22778538 Get It

Pelvic lymph node dissection is the gold standard for assessing nodal disease in prostate or bladder cancer and is superior to CT, MRI and PET staging. Endoscopic ultrasound (EUS) provides an alternative, less invasive method of cytohistologic material acquisition, but its performance in pelvic urologic malignancy is unknown. Therefore, our aim was to evaluate the diagnostic accuracy of EUS guided tissue sampling for these malignancies when compared to a composite cytohistologic and surgical gold standard. A median of 3 FNA passes were performed (n=19 patients) revealing a sensitivity, specificity, PPV and NPV of 94.4% (72–99), 100% (2–100), 100% (80–100) and 50% (1–98) respectively. The perirectal space was the most frequently sampled location irrespective of the primary urological cancer origin. Final diagnosis established by EUS tissue sampling included bladder cancer (n=1), bladder cancer local recurrence (n=8), bladder cancer extra pelvic metastases (n=1), prostate cancer (n=2), prostate cancer local recurrence (n=4), prostate cancer extra pelvic metastases (n=1), testicular cancer extra pelvic metastases (n=1) and a benign seminal vesicle (n=1). EUS guided sampling of the gut wall, lymph nodes, or perirectal space yields suitable diagnostic material to establish the presence of primary, local recurrence or extra pelvic metastases of pelvic urologic malignancy.
Barriers to Considering Ethical and Societal Implications of Research: Perceptions of Life Scientists
Boyce, Angie, Ladd, Jennifer M. , McCormick, Jennifer Blair , Cho, Mildred K.

AJOB Primary Research | June 19, 2012 | Volume: 3 | Issue: 3 | Pages: 40-50

10.1080/21507716.2012.680651 | PMID 22866239 Get It

Manganese Superoxide Dismutase Regulates a Metabolic Switch during the Mammalian Cell Cycle
Sarsour, Ehab H. , Kalen, Amanda L., Xiao, Zhen , Veenstra, Timothy D. , Chaudhuri, Leena, Reigan, Philip , Buettner, Garry R. , Goswami, Prabhat C. , Venkataraman, Sujatha , Buettner, Garry R

Cancer Research | June 19, 2012 | Volume: 72 | Issue: 15 | Pages: 3807-3816

10.1158/0008-5472.can-11-1063 | PMID 22710435 Get It

Abstract Proliferating cells consume more glucose to cope with the bioenergetics and biosynthetic demands of rapidly dividing cells as well as to counter a shift in cellular redox environment. This study investigates the hypothesis that manganese superoxide dismutase (MnSOD) regulates cellular redox flux and glucose consumption during the cell cycle. A direct correlation was observed between glucose consumption and percentage of S-phase cells in MnSOD wild-type fibroblasts, which was absent in MnSOD homozygous knockout fibroblasts. Results from electron paramagnetic resonance spectroscopy and flow cytometric assays showed a significant increase in cellular superoxide levels in S-phase cells, which was associated with an increase in glucose and oxygen consumption, and a decrease in MnSOD activity. Mass spectrometry results showed a complex pattern of MnSOD-methylation at both lysine (68, 89, 122, and 202) and arginine (197 and 216) residues. MnSOD protein carrying a K89A mutation had significantly lower activity compared with wild-type MnSOD. Computational-based simulations indicate that lysine and arginine methylation of MnSOD during quiescence would allow greater accessibility to the enzyme active site as well as increase the positive electrostatic potential around and within the active site. Methylation-dependent changes in the MnSOD conformation and subsequent changes in the electrostatic potential around the active site during quiescence versus proliferation could increase the accessibility of superoxide, a negatively charged substrate. These results support the hypothesis that MnSOD regulates a “metabolic switch” during progression from quiescent through the proliferative cycle. We propose MnSOD as a new molecular player contributing to the Warburg effect. Cancer Res; 72(15); 3807–16. ©2012 AACR.
Essential Tremor is Not a Neurodegenerative Disease
Rajput, Ali H. , Shill, Holly A. , Rajput, Alex, Adler, Charles H.

Neurodegenerative Disease Management | June 18, 2012 | Volume: 2 | Issue: 3 | Pages: 259-268

10.2217/nmt.12.23 | PMID 23105950 Get It

Single Gene Variants in Risk and Protection: A New View On the Genetic Etiology of Parkinson’s Disease
Ross, Owen A.

Neurodegenerative Disease Management | June 18, 2012 | Volume: 2 | Issue: 3 | Pages: 235-237

10.2217/nmt.12.20 Get It

Everolimus‐eluting stents and zotarolimus‐eluting stents for percutaneous coronary interventions
Ye, Zhong, Wu, Chuntao , Walford, Gary, Holmes, David R. , Jacobs, Alice K. , Stamato, Nicholas J., Venditti, Ferdinand J. , Sharma, Samin, Fergus, Icilma, King, Spencer B., Hannan, Edward L. , Sharma, Samin

Catheterization and Cardiovascular Interventions | June 18, 2012 | Volume: 81 | Issue: 7 | Pages: 1097-1105

10.1002/ccd.24512 | PMID 22707353 Get It

ObjectivesTo compare 2‐year outcomes (mortality, mortality/myocardial infarction (MI), target vessel PCI (TVPCI), and target lesion PCI (TLPCI)) for patients receiving EES and ZES.BackgroundThe utilization of drug‐eluting coronary stents (DES) among patients undergoing percutaneous coronary interventions (PCI) has increased dramatically in the last decade. Everolimus‐eluting stents (EES) and ENDEAVOR zotarolimus eluting stents (ZES) constitute the latest generation of approved DES in the United States, but little is known about their relative effectiveness.MethodsNew York patients undergoing EES and ZES revascularization without any other type of stent between 7/08 and 12/08 were propensity matched at the hospital level using multiple patient, operator, and hospital characteristics, and matched patients were followed through the end of 2010 to obtain comparative 2‐year outcomes.ResultsA total of 3286 patients were propensity‐matched. Patients receiving EES had a significantly lower TVPCI rate (9.0% vs. 11.9%, AHR = 1.31, 95% CI (1.04, 1.65)) and a significantly lower TLPCI rate (6.0% vs. 8.3%, AHR = 1.35, 95% CI (1.02, 1.79)). There was no significant difference between EES and ZES for mortality or MI/mortality.ConclusionsThere were no significant differences in the hard endpoints of death or MI between patients who received EES versus those who received ZES (ENDEAVOR). Patients with EES experienced lower repeat revascularization rates than patients with ZES at 24 months. © 2012 Wiley Periodicals, Inc.
Fish oil and neurovascular control in humans
Carter, Jason R. , Schwartz, Christopher E., Yang, Huan , Joyner, Michael J. , Carter, Jason R

American Journal of Physiology-Heart and Circulatory Physiology | June 17, 2012 | Volume: 303 | Issue: 4 | Pages: H450-H456

10.1152/ajpheart.00353.2012 | PMID 22707560 Get It

The antihypertensive influence of fish oil is controversial, and the mechanisms remain unclear. Because the inverse relation between fish oil and hypertension appears to be partially dependent on the degree of hypertension, we tested the hypothesis that fish oil would elicit more dramatic reductions in mean arterial pressure (MAP) and muscle sympathetic nerve activity (MSNA) in prehypertensive (PHT) compared with normotensive (NT) subjects. Resting MAP, MSNA, and heart rate (HR) were examined before and after 8 wk of fish oil (9 g/day; 1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid) or placebo (olive oil; 9 g/day) in 38 NT (19 fish oil; 19 placebo) and 29 PHT (15 fish oil; 14 placebo) volunteers. Fish oil did not alter resting MAP, MSNA, or HR in either NT (80 ± 1 to 80 ± 1 mmHg; 11 ± 2 to 10 ± 1 bursts/min; 71 ± 2 to 71 ± 2 beats/min) or PHT (88 ± 2 to 87 ± 1 mmHg; 11 ± 2 to 10 ± 2 bursts/min; 73 ± 2 to 73 ± 2 beats/min) subjects. When NT and PHT groups were consolidated, analysis of covariance confirmed that pretreatment resting MAP was not associated with changes in MSNA after fish oil. In contrast, pretreatment resting HR was correlated with changes in MSNA ( r = 0.47; P = 0.007) and MAP ( r = 0.42; P < 0.007) after fish oil but not placebo. In conclusion, fish oil did not alter sympathetic neural control in NT or PHT subjects. However, our findings suggest that fish oil is associated with modest sympathoinhibition in individuals with higher resting heart rates, a finding that is consistent with a recent meta-analysis examining the relations among fish oil, HR, and the risk of cardiovascular disease.